Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2019-11-06 Foreign Filer Report
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
6-K
Foreign Filer Report
2019-11-06 English
Genmab Announces Financial Results for the First Nine Months of 2019
Report Publication Announcement Classification · 95% confidence The document is an announcement regarding the release of an 'Interim Report for the First Nine Months Ended September 30, 2019'. While it contains some financial highlights and guidance, it explicitly states at the end: 'Download the full Interim Report for the First Nine Months of 2019 on attachment or at www.genmab.com' and provides a link to the attachment. Following the 'Menu vs Meal' rule, this document serves as an announcement of the report rather than the full report itself, making it a Report Publication Announcement (RPA). 9M 2019
2019-11-06 English
6-K
Foreign Filer Report
2019-10-30 English
David Eatwell to Retire as Chief Financial Officer of Genmab
Board/Management Information Classification · 100% confidence The document is a formal company announcement regarding the retirement of the current CFO and the appointment of a successor. This falls directly under the category of changes in senior management. While the document mentions an attachment, the core content is the announcement of the management change itself, which is the primary purpose of the filing.
2019-10-30 English
Board/Management Information 2019
Board/Management Information Classification · 99% confidence The document is titled "David Eatwell to Retire as Chief Financial Officer of Genmab" and is explicitly labeled as a "Company Announcement." It details a change in senior management: the retirement of the CFO and the appointment of his successor, effective on specific future dates. This content directly aligns with the definition of Board/Management Information (MANG), which covers announcements of changes in senior management.
2019-10-30 English
David Eatwell to Retire as Chief Financial Officer of Genmab
Board/Management Information Classification · 98% confidence The document is a 'Company Announcement' from Genmab A/S detailing the retirement of the CFO, David Eatwell, and the appointment of his successor, Anthony Pagano, effective March 1, 2020. It also mentions the initiation of a search for a COO. This content directly relates to changes in the company's senior management and board structure. This aligns perfectly with the definition for Board/Management Information (MANG). The document is not a full financial report (10-K or IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2019-10-30 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.